v3.25.4
Cover Page - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Feb. 27, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Entity Central Index Key 0002081043    
Entity Registrant Name AtaiBeckley Inc.    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Trading Symbol ATAI    
Title of 12(b) Security Common stock, par value $0.01 per share    
Security Exchange Name NASDAQ    
Entity Filer Category Non-accelerated Filer    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
Entity File Number 001-43037    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One c/o atai Life Sciences US, Inc.    
Entity Address, Address Line Two c/o Industrious NYC    
Entity Address, Address Line Three 250 West 34th Street    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
City Area Code 332    
Local Phone Number 282-0507    
Entity Address, Postal Zip Code 10119    
Entity Tax Identification Number 41-3357923    
Entity Public Float     $ 361.3
Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Common Stock, Shares Outstanding   364,745,985  
Auditor Firm ID 34    
Auditor Name DELOITTE & TOUCHE LLP    
Auditor Location New Jersey    
Auditor Opinion

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of AtaiBeckley Inc. and subsidiaries (the "Company") as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows, for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

   
Documents Incorporated By Reference TextBlock

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive proxy statement relating to its 2026 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the "SEC") within 120 days after the end of the fiscal year ended December 31, 2025, are incorporated herein by reference in Part III where indicated.